Alzheimer's disease is usually associated with old age. But around 5%-10% of all Alzheimer's cases occur in people under the age of 65. Early-onset ...
The European Medicines Agency has rejected Lilly’s Alzheimer’s drug Kisunla for a license, saying its benefits don’t outweigh the risk of brain swelling or bleeding. The treatment for early ...
“The benefits of Kisunla were not large enough to outweigh the risks of potentially fatal events,” the agency said, citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback